Last updated on December 2019

BI655130 (SPESOLIMAB) Induction Treatment in Patients With Moderate-to-severe Ulcerative Colitis


Brief description of study

This trial has two sequentially enrolling parts with different objectives. The primary objectives of this trial are

  • to prove the concept of clinical activity of BI 655130 in patients with moderate-to-severely active ulcerative colitis who have failed previous biologic treatments and to identify efficacious and safe dose regimens in Part 1 (Phase II)
  • to confirm efficacy and safety of BI 655130 in patients with moderate-to-severely active ulcerative colitis who have failed previous biologic treatments in Part 2 (Phase III)
  • To provide, along with induction study 1368-0018 and the run-in cohort of 1368-0020, the target population to be evaluated in study 1368-0020.

Clinical Study Identifier: NCT03482635

Find a site near you

Start Over

Tokyo Yamate Medical Center

Tokyo, Shinjuku, Japan
7.98miles
  Connect »

Tokyo Medical and Dental University

Tokyo, Bunkyo-ku, Japan
9.4miles
  Connect »